6h agoThe FlyBEARISH 38Earnings
Archived explainer. For the current picture see today's ASND page.
Why Is ASCENDIS PHARMA A/S (ASND) Stock Down Today?
By the Top Tier Newswire AI Desk · September 15, 2026 at 10:57 AM ET · reviewed against 9 wire stories
ASCENDIS PHARMA A/S (ASND) is down -13.11% in the latest session. Our newswire has captured 9 stories on ASND across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ASND stock is down today
Ascendis Pharma A/S stock fell by 13.11% to $230.18 in early trading on Friday, marking one of the most significant declines in its recent history. The move followed a Raymond James downgrade of the stock from Strong Buy to Outperform, which came amid a broader shift in the company's partnership strategy. The stock opened with a 2.4% gap down and continued to fall throughout the session, reaching a low of $229.03 before stabilizing slightly in the final minutes.
What Happened
Raymond James downgraded Ascendis Pharma's stock rating on the back of a strategic shift in its partnership structure. The firm cited the termination of the collaboration agreement with Novo Nordisk, which occurred in November 2024, as a key factor. This move led to the company regaining rights to its TransCon technology-based products. While the firm acknowledged the $400 million share repurchase program announced by the company, it viewed the strategic shift as a negative for the stock's momentum. The downgrade came as a surprise to many market participants and triggered a sharp sell-off. Additionally, the recent insider sale by SVP Mads Bodenhoff on September 8 may have contributed to investor caution.
What The Data Shows
The stock opened at $258.50 and quickly moved lower, hitting a session low of $229.03. The volume of 0.7 million shares was above the 3-month average by 10%. The stock has traded within a 52-week range of $186.05 to $282.15 and is currently trading near the lower end of that range. Over the last eight sessions, the stock had moved up slightly by 0.3%, but the recent selloff reversed that trend. The stock has now hit 19 fresh 52-week lows on September 15, indicating growing bearish sentiment. The repurchase program and the termination of the Novo Nordisk deal are expected to have a material impact on the company's future valuation and earnings trajectory.
What To Watch
The company has not scheduled earnings in the near term, but investors will be watching for broader coverage shifts and analyst reactions to the Raymond James downgrade. The $400 million share repurchase program and the strategic realignment of partnerships will be key factors in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ASND by the numbers
Last: $230.18Session: -13.11%7 sessions: -13.81%Coverage: 9 stories / 6 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $17.3BP/E: 19.852w: $186.05 to $282.15
The headlines behind the move
10h agoThe FlyBEARISH 42Analyst
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James
12h agoInvesting.com Analyst RatingsBEARISH 38Analyst
Raymond James downgrades Ascendis Pharma stock rating on partnership shift
Raymond James downgrades Ascendis Pharma stock rating on partnership shift
12h agoSeeking AlphaBULLISH 71General
Ascendis Pharma sets $400M stock buyback plan
Ascendis Pharma (ASND) authorizes a $400M share repurchase program, flexible and adjustable anytime.
21h agoMorningstarBULLISH 67General
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis.
22h agoThe FlyBULLISH 71General
Ascendis Pharma announces $400M share repurchase plan
22h agoThe FlyBULLISH 63General
Ascendis Pharma to regain rights to TransCon technology-based products
22h agoBusiness InsiderBULLISH 71General
Ascendis Announces Planned $400 Million Share Repurchase Program
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ASND: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ASND move explainers: 2026-09-15 · 2026-09-01 · 2026-08-31